Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...

Precursor for Semiconductor Market is Segmented by Type (Silicon Precursor, Metal Precursor, High-k Precursor, Low-k ...

India], September 11: Merck Foundation, the philanthropic arm of Merck KGaA Germany officially launched their programs in Botswana in partnership with NEO JANE MASISI, The First Lady of Botswana, who ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

In July, Bangalore Rural MP Dr C N Manjunath, also a cardiologist, urged the Karnataka Government to declare dengue as a state medical emergency amid rising cases. He had warned that if the mosquito ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

20. Merck’s BTK inhibitor last December failed to beat off-patent Aubagio on efficacy in MS trials, hitting confidence in the wider drug class. Roche subsidiary Genentech is still in the race ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Gold prices continued to rise in Bangalore on Thursday, August 29, 2024, with 24K, 22K and 18K yellow metal prices reaching their highest level of the month. Silver prices jumped too with 1Kg of ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.